Navigation Links
Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Date:4/15/2008

>

"MEK inhibitors may have broad utility in the treatment of human cancers and inflammatory diseases. We are pleased to have two compounds in this class, both with excellent preclinical profiles and promising human pharmacokinetics, moving forward in clinical development," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We constantly strive to diminish the inherent risk of drug development by having multiple compounds, from structurally different chemical classes, moving through development and we are excited to complete Phase 1 testing of our lead MEK inhibitor, RDEA119, and progress RDEA436 into Phase 1 clinical testing, in the second half of 2008."

The posters are available on the Company website (http://www.ardeabio.com/) under the titles "RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies" and "RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties."

About RDEA119 and RDEA436

RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data shows that RDEA436 is a potent in vitro and in vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.

About Ardea Biosciences

Ardea
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 The Physician-Patient Alliance for Health ... 28, 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance ... Safety." A sentence was omitted from ... "PPAHS is a member of the National Coalition ... information on the National Coalition to Promote Continuous Monitoring ...
(Date:7/31/2015)... 2015  Xcelience, a contract development and manufacturing ... a structured cash investment in Powdersize, a ... micronization and powder size classification within the pharmaceutical ... while simultaneously adding a complete set of particle ... "As we continue to build ...
(Date:7/31/2015)... Ore., July 31, 2015  Semler Scientific, Inc. (Nasdaq: ... testing services to healthcare insurers and physician groups, today ... 30, 2015. "In the second quarter ... year revenue growth of 54%, quarter over quarter revenue ... the installed base of FloChec® units of 18%," said ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids ... are now being treated at Florida Hospital Tampa with the device that provides ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Patients with higher ... to a study published today in Nature Communications and led by researchers from the ... suggests that variations in the gene RTN1 led to greater production of the related ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... NB (PRWEB) , ... July 31, 2015 , ... Indosoft, ... script builder in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system ... that the agent script display logic shows the script components to the agent only ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... release a newly redesigned website at Healthpointe.net. The new website will feature a ... , The redesign serves to provide smoother interactions between patients and the Healthpointe ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Healthpointe Announces Newly Redesigned Website 2
... a technique to attack and destroy tumours without causing ... hair loss. ,They have used nanotechnology to ... leave healthy tissue unaffected. ,The particles - ... they zero in on their target. ,Traditional ...
... A chemical emergency struck Salisbury, suburb north of the Adelaide ... a five-year-old kid , sliding down in a popular ... ,It is not clear what happened to the ... out something had gone wrong. ,Health authorities described ...
... out of care do not live as long as those ... Medicine and Veterans Affairs researchers in a report published ... available on line. ,"In an era when highly ... causes AIDS) is keeping people alive, understanding the value of ...
... Britain have developed an artificial plastic blood, which they claim ... be a huge advantage in war zones. ... that have an iron atom at their core, like haemoglobin, ... researchers say they were looking for extra funding to develop ...
... for a Tasmanian school was convicted to a four-month jail ... and making pornography out of it. ,Adrian Alan ... indecency, one count of producing child exploitation material, and one ... used the school's own camera to take 36 pictures of ...
... To help people understand who is at risk for the disease, ... up some common myths about osteoporosis. ,1. MYTH: ... many more women who may develop this condition, theres also a ... In fact, roughly 2 million men suffer from osteoporosis, accounting for ...
Cached Medicine News:Health News:New Cancer Therapy That can Be Less Painful 2Health News:Children Using Slide in Playground Treated for Exposure to Poisoning 2Health News:HIV Survival Improves If Patients Stay in Care 2Health News:7 Common Myths About Osteoporosis 2Health News:7 Common Myths About Osteoporosis 3
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... Provides reliable strength for temporary wound ... which compliant and stretchable support material ... transudate is not required. Predictable absorption. ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL ...
... Mesh plugs perform best when the ... contact with a smooth wall of highly ... means less tissue remodeling to help stabilize ... fills more of the defect with gentle ...
Medicine Products: